Surveillance for hepatocellular carcinoma: A standard of care, not a clinical option

Hepatology

Volumn 54, Issue 6, 2011, Pages 1898-1900

  Sangiovanni, Angelo ^a   Colombo, Massimo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ALCOHOL LIVER DISEASE; BELGIUM; CANCER EPIDEMIOLOGY; CANCER SCREENING; EDITORIAL; FRANCE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATIENT CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INFORMED CONSENT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82455168095     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24684     Document Type: Editorial

References (13)

1. Kim WR, Gores GJ, Benson JT, Thernau TM, Melton LJ. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005; 129: 486-493.
2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; for EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-430.
3. ®). Bethesda, MD: National Cancer Institute. Updated July 16, 2010. Accessed September 14, 2011.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
5. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474
6. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
7. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al.; for Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997.
8. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11: 1-206.
9. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. HEPATOLOGY 2003; 37: 520-527.
10. Ganne-Carrié N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996; 23: 1112-1118.
11. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 2011; 54: 1998-2004.
12. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52: 132-141.
13. Davila J, Henderson L, Kramer J, Kanwal F, Richardson P, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154: 85-93.